The Freedom Stack: Mechanism of Action

Reported Mechanisms — Component by Component

Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here.

1. GLP3-R / Retatrutide (30 mg, 1 vial) — Triple Receptor Agonism

Retatrutide is described as engaging the GIP, GLP-1, and glucagon receptors with a single peptide sequence — the feature that distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism.[1] Clinical pharmacology has been reported in a phase 1b multiple-ascending-dose trial and in phase 2 studies of the pharmaceutical formulation.[2][3][4]

2. SS-31 / Elamipretide (100 mg across 2 vials) — Cardiolipin Interaction

SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin, the signature phospholipid of that membrane. Birk et al. reported that this interaction re-energizes ischemic mitochondria and that targeting the cytochrome c/cardiolipin complex promotes electron transport and mitochondrial ATP synthesis.[6][7] Campbell et al. reported effects on age-related redox stress and exercise tolerance in aged mice, Chiao et al. reported late-life restoration of mitochondrial function in old mice, and Sabbah et al. reported effects on left ventricular and mitochondrial function in a canine heart-failure model.[8][9][10]

3. KLOW (160 mg across 2 vials) — Four-Peptide Tissue-Repair Blend

Each KLOW vial contains four peptides with distinct reported targets. GHK-Cu (50 mg) coordinates Cu(II) and has been reported to modulate broad gene-expression programs and matrix proteins.[12][13][14] BPC-157 (10 mg) has been associated with VEGFR2 activation in endothelial models.[15][16] TB-500 (10 mg) carries the actin-binding motif of Thymosin β4.[17][18] KPV (10 mg) is the C-terminal α-MSH tripeptide studied for anti-inflammatory activity and PepT1-mediated uptake.[19][20]

No published pharmacokinetic, pharmacodynamic, or interaction study has evaluated retatrutide, SS-31, and the KLOW peptides administered together. Any combined behaviour is unstudied.